Philip Morris International (PM) has seen a diverse range of investments, partnerships, analysis, and anticipation surrounding its stock. Major fund management and advisory firms have significantly increased or reduced their holdings in PM - Ninety One UK Ltd, Thomasville National Bank, AE Wealth Management, State of Alaska Department of Revenue, HF Advisory Group, and many more.
Smoke-free products, contributing to 41.5% of the company’s revenue after 2025 results, are driving the valuation and investment narrative. PM’s recent strategic commercial partnership with
Ferrari Hypersail is reframing its innovation narrative and building on their 50-year relationship. Furthermore, a gradual shift from tobacco to ZYN and a focus on enhanced smoking cessation efforts echo PM's endeavor to move away from cigarettes. The U.S.
FDA reauthorized its IQOS as a modified risk tobacco product, positioning PM for potential long-term success. However, recent FDA scrutiny delayed the review of nicotine pouches, which slightly dampened market sentiment. Despite setbacks, most analysts give PM a 'Moderate Buy', with price targets up to $200 and projections of an upside surprise from the upcoming Q1 2026 results.
Philip Morris International PM News Analytics from Wed, 28 Jan 2026 08:00:00 GMT to Sat, 18 Apr 2026 12:11:52 GMT -
Rating 6
- Innovation 5
- Information 7
- Rumor 1
